Stockreport

Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects [Yahoo! Finance]

Belite Bio, Inc - American Depositary Shares  (BLTE) 
PDF modifications, maintaining the sample size at 104 subjects following a planned interim efficacy analysis; trial completion expected by Q4 2025 (including a three-month f [Read more]